Ferring Pharmaceuticals

Ferring Pharmaceuticals, a Swiss biopharmaceutical firm with manufacturing operations across nine countries, had built its batch production and quality assurance regime on a paper-based batch record system — standard practice for companies of its generation but increasingly untenable at scale. In a heavily regulated industry where FDA and EMA compliance requires exhaustive documentation, paper introduced latency at every step: the time from batch manufacture to product release stretched to 44 days or more. With industry-wide manufacturing lead times already running 120–180 days, Ferring's own lead time was notably long even by that benchmark, threatening its competitive position and time-to-market as its product portfolio grew.

Beginning in 2010, Ferring implemented an electronic batch record (eBR) solution at its flagship facility in Saint-Prex, Switzerland, using FactoryTalk® PharmaSuite™ from Rockwell Automation. The deployment replaced paper-based batch documentation with a digital MES layer that captured process data in real time, governed by the batch recipe acting as a defined production blueprint. Any deviation from recipe parameters surfaced immediately on operations dashboards, enabling qualified personnel to conduct quality review concurrently with manufacturing rather than after the fact. Rockwell Automation's platform was subsequently integrated with Ferring's broader IT infrastructure — including laboratory information management and enterprise systems — creating an end-to-end MES. The rollout began at Saint-Prex with plans to extend across Ferring's international network and two new facilities under construction in the United States and India.

Over the five years following the 2010 eBR deployment, Ferring's Saint-Prex facility increased annual batch output from 7,000 to 11,000 batches — a 56% improvement achieved with the same headcount, representing a direct return on investment without additional labor cost. Time in process was cut in half, addressing the QA/QC bottleneck that had been the primary driver of extended lead times. Qualitative outcomes were equally significant:

• Real-time process visibility enabled exception-based quality management during production
• QA/QC review shifted from a post-manufacture queue to an inline activity
• The foundation was established for full IT/OT integration across Ferring's international supply chain
• Regulatory compliance confidence improved through automated, auditable batch records

• Start with the record, not the line. Ferring's gains came from digitizing batch documentation first — eBR unlocked MES value by making process data available in real time before broader automation was tackled.
• Concurrent QA review is the throughput lever. Moving quality review from post-manufacture to inline is where pharmaceutical manufacturers recover the most time in process.
• Plan for IT integration from day one. FactoryTalk's value compounded when connected to LIMS and enterprise systems; treating MES as a standalone deployment limits long-term ROI.
• Multi-site rollout requires a proven flagship. Ferring validated the approach at Saint-Prex before committing to international expansion — a low-risk sequencing model worth replicating.